(62) confirmed that the detection of serum soluble urokinase plasminogen activator receptor (uPAR) at baseline and after treatment could be a predictive biomarker for evaluating the efficacy of TNFi ADA in patients with RA. Here, PLAUR is linked to rheumatoid arthritis.